Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DL6EZ5
|
|||
| Drug Name |
AG019
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Type-1 diabetes [ICD-11: 5A10] | Phase 1/2 | [1] | |
| Company |
Intrexon T1D Partners; ActoBio Therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03751007) A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.